Fischer, Alessa
Bankel, Lorenz
Hiltbrunner, Stefanie
Rechsteiner, Markus
Rüschoff, Jan H.
Rushing, Elisabeth Jane
Britschgi, Christian
Curioni-Fontecedro, Alessandra http://orcid.org/0000-0002-5778-5270
Funding for this research was provided by:
University of Zurich
Article History
Accepted: 4 September 2022
First Online: 22 September 2022
Declarations
:
: This study was supported by the ‘Stiftung für angewandte Krebsforschung’ Zürich.
: Alessa Fischer, Lorenz Bankel, Stefanie Hiltbrunner, Markus Rechsteiner, Jan Rüschoff, Elisabeth Rushing, and Christian Britschgi declare they have no conflicts of interest that might be relevant to the contents of this manuscript. Alessandra Curioni-Fontecedro reports honoraria for lectures and advisory fees from Astra Zeneca, BMS, Boehringer Ingelheim, MSD, Pfizer, Roche, and Takeda.
: This study was conducted according to the law and regulations of the local Ethics Commission under reference number KEK ZH-2021-00381. All patients included in the study consented to their participation.
: The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.
: Not applicable.
: Conceptualization: AF, LB, SH, ACF. Methodology: AF, ACF, MR. Investigation: AF, JR. Data curation: AF, MR. Validation: LB, ACF. Formal analysis: AF. Visualization: AF, SH. Resources: SH, MR, ER, ACF. Writing: AF, ACF. Review and editing: LB, SH, MR, JR, ER, CB, ACF. Supervision: ACF. Funding acquisition: SH, ACF.